On May 7, 2018, Impax Laboratories, Inc. combined with Amneal Pharmaceuticals, Inc. (NYSE:AMRX) to create a dynamic company powered by a robust U.S. generics business and growing branded franchise. Today, we are working to integrate our business into the new Amneal and are excited about our future as one company.
In the meantime, we continue with Impax’s announced commitments to clinical activities, including:
|IND||Phase 1||Phase 2||Phase 3||Approved|
Pediatric Migraine Ages 6-11
Parkinson’s Disease Symptoms
Additional information regarding the pipeline at Impax Laboratories can be found at Press Releases.